It is unknown how treatment with radical prostatectomy (RP) and adjuvant external beam radiotherapy (EBRT), androgen deprivation therapy (ADT), or both (termed MaxRP) compares with treatment with EBRT, brachytherapy, and ADT (termed MaxRT).
W hile a large randomized trial 1 comparing radical prostatectomy (RP) with external beam radiotherapy (EBRT) for the treatment of men with favorablerisk prostate cancer has been performed and reported, a large randomized clinical trial is lacking in men with high-risk prostate cancer.
2 Evidence available to address this treatment decision comes from a multi-institutional retrospective study, 3 which reported an association between a reduced risk of prostate cancer-specific mortality (PCSM) among men with highrisk prostate cancer based on biopsy Gleason score 9-10 prostate cancer and treatment with the combination of EBRT, brachytherapy, and androgen deprivation therapy (ADT) (termed MaxRT) for a median of 12 months compared with RP. However, a study comparing MaxRT with RP and adjuvant EBRT, ADT, or both (termed MaxRP) has not been performed, to our knowledge. These comparisons are important because 3 randomized clinical trials [4] [5] [6] have shown a significantly prolonged diseasefree survival when adjuvant EBRT is administered compared with observation in men found to have extraprostatic extension, seminal vesicle invasion, and/or a positive surgical margin (R1) in the RP specimen. Moreover, another randomized study 7 reported a survival benefit when adjuvant ADT was used compared with observation in the postoperative setting of pelvic lymph node-positive (N1) prostate cancer. Therefore, we investigated whether treatment of Gleason score 9-10 prostate cancer with RP and adjuvant EBRT, ADT, or MaxRP vs MaxRT was associated with PCSM and all-cause mortality (ACM) risk.
Methods

Patient Population and Treatment
The study cohort comprised 639 men (mean [SD] age of 65.83 [6.52] years) with clinical T1-4,N0M0 (as per pelvic imaging and bone scan) biopsy Gleason score 9-10 prostate cancer. Between February 6, 1992, and April 26, 2013, a total of 80 men were consecutively treated with MaxRT at the Chicago Prostate Cancer Center (Westmont, Illinois), and 559 men were consecutively treated with RP and pelvic lymph node dissection at the Martini-Klinik Prostate Cancer Center (Hamburg, Germany). Men included in the study had a minimum follow-up of 6 months and a maximum follow-up of 8 years and initiated treatment within 4 to 6 weeks of diagnosis. Of the 559 men managed with RP and pelvic lymph node dissection, 372 (66.5%) received RP, 88 (15.7%) received RP plus adjuvant radiotherapy (RT) (ie, for prostate-specific antigen [PSA] level <0.1 ng/mL), 50 (8.9%) received MaxRT, and 49 (8.8%) received RP plus adjuvant ADT (to convert PSA level to micrograms per liter, multiply by 1.0). Androgen deprivation therapy consisted of a luteinizing hormone-releasing hormone agonist or an antagonist with or without an antiandrogen and was delivered for a median duration of 6.00 months (interquartile range [IQR], 4.00-12.00 months) in men undergoing MaxRT. After RP, men found to have negative pelvic lymph nodes had a median ADT duration of 8.60 months (IQR, 4.70-19.80 months), and men found to have positive pelvic lymph nodes had a median ADT duration of 14.45 months (IQR, 7.00-23.90 months). External beam radiotherapy was delivered using photons in 25 fractions of 1.8 Gy to the prostate and seminal vesicles with a computed tomography-based simulation and intensity-modulated RT technique. Pelvic lymph node RT was delivered based on tumor characteristics at the discretion of the treating physician (B.J.M. (IQR, (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Adjuvant RT was delivered using EBRT at a median of 3.32 months (IQR, 2.60-4.14 months) after RP to the prostatic bed to a median dose of 68.4 Gy; when involved, the pelvic lymph nodes were initially treated to a total dose of 45.0 Gy. Adjuvant ADT was given a median of 0.95 months (IQR, 0.43-2.43 months) after RP and was recommended when more than 1 lymph node was involved.
7 Salvage RT to the prostate and seminal vesicles bed was administered after post-RP PSA failure (PSA level >0.1 ng/mL) unless the patient previously had adjuvant RT, in which case salvage ADT was delivered. After MaxRT, salvage ADT was administered for PSA failure. 8 Salvage RT and/or ADT was initiated within 3 months after documented PSA recurrence and always before symptomatic or radiographic progression. Prostate needle biopsy specimens and prostatectomy specimens underwent review by a pathologist with expertise in genitourinary pathology at each center. This study was approved by the Ethik-Kommission der Ärztekamme institutional review board in Hamburg, Germany, and by the IntegReview institutional review board in Austin, Texas. In accord with federal and institutional guidelines, all men before study entry signed an institutional review boardapproved, protocol-specific informed consent form permitting collection of deidentified patient data at baseline and
Key Points
Question Can treatment with radical prostatectomy, adjuvant external beam radiotherapy, and androgen deprivation therapy (termed MaxRP) or external beam radiotherapy, brachytherapy, and androgen deprivation therapy (termed MaxRT) in men with Gleason score 9-10 prostate cancer provide similar survival outcomes?
Findings Among 639 men, this cohort study found no significant difference after MaxRP or MaxRT in prostate cancer-specific and all-cause death risk, with plausibility indexes for equivalence of 76.75% for prostate cancer-specific mortality risk and 77.97% for all-cause mortality risk.
Meaning It is plausible that treatment with MaxRP or MaxRT for men with Gleason score 9-10 prostate cancer provides equivalent survival outcomes.
follow-up, which were entered into a secure, passwordprotected database for subsequent outcome analysis.
Follow-up and Determination of the Cause of Death
Follow-up started on the day of prostate EBRT or RP and concluded on October 27, 2017, or the date of death, whichever came first; no patient was lost to follow-up. During follow-up, patients had a PSA test and rectal examination and were seen every 3 months for 1 year, every 6 months for an additional 4 years, and then annually thereafter. To record a death from prostate cancer, castrate-resistant metastatic prostate cancer based on a rising PSA level in the setting of a testosterone level less than 20 ng/ dL before death needed to be confirmed (to convert testosterone level to nanomoles per liter, multiply by 0.0347). 11 The distribution of the follow-up times was calculated using the method by Kaplan and Meier, 12 and comparisons of these distributions across men treated using RP-based vs MaxRT therapy were made using the generalized Wilcoxon test for comparing 2 censored samples.
Statistical Analysis
13,14
Treatment Univariable and Multivariable Hazard Ratios for the Risk of PCSM and ACM Univariable and multivariable regression using methods by Cox 15 and by Fine and Gray 16 were used to evaluate whether PCSM risk and ACM risk, respectively, were significantly associated with treatment, adjusting for year of treatment, treatment propensity score (PS), 17 and salvage therapy. Time zero was defined as the date of RP or the first day of MaxRT. The continuous covariate year of treatment was included in the model to adjust for any potential changes in patterns of care over time. The treatment PS was included in the model to ensure that the distributions of the baseline clinical characteristics between all RP-containing vs MaxRT treatments were balanced. The outcome for the PS was the treatment received (RP containing vs MaxRT), and the covariates included in the PS were prostate cancer prognostic factors, including the baseline PSA level (continuous), biopsy Gleason score (4 + 5 vs 5 + 4 vs 10), and American Joint Commission on Cancer (AJCC) tumor category (T3,4 vs T2 vs T1c), and patient factors, including age (>70 vs ≤70 years) and cardiometabolic comorbidity (minimal or moderate vs none) using the Adult Comorbidity Evaluation 27 (ACE-27) metric. 18 Each patient had a detailed history and physical examination at the time of prostate cancer diagnosis, on which the ACE-27 score was based and assigned retrospectively at the time of the study analysis. Cardiometabolic comorbidity was categorized as moderate if the patient had a history of congestive heart failure and/or an acute myocardial infarction more than 6 months before the diagnosis of prostate cancer. No patient was reported to have had a history of congestive heart failure or an acute myocardial infarction within 6 months of the diagnosis of prostate cancer. Of the 639 men in the study cohort, 533 (83.4%) had no comorbidity, 101 (15.8%) had minimal comorbidity, and 5 (0.8%) had moderate comorbidity. Timedependent treatment covariates 15 for treatment with MaxRP were used to assess PCSM and ACM risk after these treatments, as well as RP alone compared with treatment with MaxRT. An adjustment for the use of salvage RT and/or ADT using time-dependent covariates was also included in the models. For the models by Fine and Gray 16 and by Cox, 15 an event was defined as prostate cancer and any death, respectively. The assumptions of both the model by Cox 15 and the model by Fine and Gray 16 were tested, and no evidence was found that these assumptions were violated. Unadjusted and adjusted hazard ratios (AHRs) for PCSM and ACM, with associated 95% CIs and P values, were calculated for each covariate.
Assessment of the Likelihood of Equivalence for the Risk of PCSM and ACM Between Treatments
Given the AHRs and associated 95% CIs for treatment with MaxRP compared with MaxRT for the end points of PCSM and ACM, the plausibility index defines the likelihood that the true AHR equals 1.00, reflecting equivalence. The plausibility index was calculated for each treatment compared with MaxRT. The plausibility index can have a value between 0 and 1, corresponding to the least and the most likely chance, respectively, that the risk of PCSM and/or ACM between 2 treatments is equivalent (eMethods and eFigure in the Supplement).
Estimates of PCSM and ACM Estimates of PCSM (cumulative incidence) and ACM (1 minus Kaplan-Meier estimates of overall survival) after the day of MaxRT initiation or RP stratified by time-dependent treatment groups were calculated using the extended KaplanMeier method with time-dependent covariates 19 and adjusting for the year of treatment and the treatment PS. 20 A 2-sided P < .05 was considered statistically significant, and a Bonferroni adjustment 21 was applied for multiple comparisons (P < .05 divided by 4, or P < .01). R (version 3.4.4; R Foundation for Statistical Computing) was used for all calculations pertaining to cumulative incidence functions and Kaplan-Meier estimates with time-dependent treatment covariates. Version 3.4.1 of R was used to calculate the plausibility index. SAS (version 9.4; SAS Institute Inc) was used for all other calculations.
Results
Comparison of the Distribution of Clinical and Pathologic Characteristics
As summarized in Table 3 , the risk of PCSM and ACM was increased in men undergoing RP compared with MaxRT (2.80; 95% CI, 1.26-6.22; P =. 0 1f o r PCSM and 1.65; 95% CI, 0.94-2.91; P = .08 for ACM). However, there was no significant difference in these risks when comparing men who underwent RP plus adjuvant RT (0.52; 95% CI, 0.14-1.98; P = .34 for PCSM and 0.70; 95% CI, 0.31-1.57; P = .39 for ACM) or MaxRP (1.33; 95% CI, 0.49-3.64; P = .58 for PCSM and 0.80; 95% CI, 0.36-1.81; P =. 6 0f o r ACM) vs MaxRT. Nevertheless, men who underwent RP plus adjuvant ADT had a significantly increased risk of PCSM and ACM compared with men who underwent MaxRT (3.15; 95% CI, 1.32-7.55; P = .01 for PCSM and 2.33; 95% CI, 1.23-4.42; P = .01 for ACM). 
Assessment of the Likelihood of Equivalence for the Risk of PCSM and ACM Between Treatments
As summarized in Table 4 , the plausibility index for equivalence was highest for the treatment comparison of MaxRP with MaxRT, being 76.75% for the end point of the risk of PCSM and 77.97% for the end point of the risk of ACM. For all other treatment comparisons, these respective values ranged from 4.75% to 58.24% and from 4.62% to 62.32%.
Estimates of PCSM and ACM
As shown in the Figure, 
Discussion
In this study, we first validated the prior finding 3 of a significantly reduced PCSM risk in men with biopsy Gleason score 9-10 prostate cancer when treated using MaxRT compared with RP but with a median ADT duration of 6 months as opposed to 12 months. Specifically, the point estimate of the AHR for the risk of PCSM comparing MaxRT with RP in the present study was 0.36 (1 divided by 2.80), which is similar to the previous report 3 of 0.38. While prospective validation is needed in a randomized clinical trial, this result provides evidence to support that, in the setting of EBRT and brachytherapy, adding 6 months compared with 12 months of ADT may provide a similar PCSM risk reduction compared with RP. Second, when assessing the likelihood of equivalence in the risk of PCSM and ACM after treatment using the plausibility index, men undergoing MaxRP had the highest likelihood of achieving equivalent risk of PCSM and ACM compared with men undergoing MaxRT. Lending further support to this result, we observed that, despite having more adverse postoperative prostate cancer prognostic factors compared with men undergoing RP, who fared worse than men undergoing MaxRT, men undergoing MaxRP did not have an increased risk of PCSM or ACM when compared with men undergoing MaxRT, whereas men who underwent RP plus adjuvant ADT without EBRT did. The clinical significance of these observations is that they provide evidence to support the importance of adding both adjuvant EBRT and ADT after RP in men with biopsy Gleason score 9-10 prostate cancer to reduce the risk of PCSM and ACM so that their outcomes may become comparable to those of men undergoing MaxRT.
Some points require further discussion. First, while not significant, men undergoing RP plus adjuvant RT had an AHR for PCSM and ACM risk less than 1.0, which can be explained by the more favorable baseline distribution of prostate cancer prognostic factors in men undergoing RP plus adjuvant RT vs MaxRT, in Abbreviations: ACM, all-cause mortality; ADT, androgen deprivation therapy; AHR, adjusted HR; EBRT, external beam radiotherapy; MaxRP, RP and adjuvant EBRT, ADT, or both; MaxRT, EBRT, brachytherapy, and ADT; NA, not applicable;
PCSM, prostate cancer-specific mortality; PS, propensity score; RP, radical prostatectomy; RT, radiotherapy; (t), time-dependent treatment.
addition to the significantly shorter median follow-up of 3.87 vs 5.51 years (P = .03), providing less time to observe deaths. Moreover, when treatment with RP plus adjuvant RT was evaluated for possible equivalence with MaxRT using the plausibility index, the values were 58.24% and 62.32% for the risk of PCSM and ACM, respectively, which were lower compared with the respective values of 76.75% and 77.97% for men treated with MaxRP. Second, while a prior study 22 has shown that at least 75% of men undergoing RP for biopsy Gleason score 9-10 prostate cancer will have at least 1 adverse pathologic factor at RP (ie, extraprostatic extension, seminal vesicle invasion, R1, or N1) and thus have an indication for adjuvant EBRT and/or ADT, only 33.5% (187 of 559) of men received adjuvant EBRT, ADT, or both in the present study. The reason for the low use of adjuvant EBRT in the post-RP setting arises from the concerns regarding overtreatment in the current era in which PSA monitoring after RP is routinely practiced and early salvage EBRT at the time of PSA failure can occur. Specifically, the 3 randomized adjuvant EBRT trials 4-6 were conducted during the pre-PSA and early PSA era. 
Strengths and Limitations
The strength of our study is the adjustment for the use of adjuvant and salvage therapies using time dependent covariates enabling a comparison of Max RT with Max RP with respect to the endpoints of PCSM and ACM-risk. A limitation is the lack of randomization.
Conclusions
Given no ongoing or planned randomized equivalence trials, to our knowledge, comparing PCSM and ACM after MaxRP vs MaxRT for men with biopsy Gleason score 9-10 prostate cancer, our results herein are important. They provide the only available evidence to date to support that it is plausible that treatment with MaxRP or MaxRT can lead to equivalent risk of PCSM and ACM in men with biopsy Gleason score 9-10 prostate cancer.
eMethods. Supplemental Methods
Description of the Plausibility Index
The analysis. Specifically, the p-value represents the probability that the null hypothesis: "there is no difference in the risk of PCSM or ACM between the 2 treatments being compared" is true.
So the smaller the p-value (e.g. a p < 0.05 or our current standard for rejecting the null hypothesis and concluding that the there is a significant difference in the risk of PCSM for the 2 treatments being compared) the less likely it is that the true AHR equals 1.0 and therefore the lower the plausibility index. Specifically, for a p < 0.05 there is < 5% chance that there no difference in the risk of PCSM following these 2 treatments as was the case for RP and ADT versus MaxRT where the p-value was 0.01 and the plausibility index that the true AHR = 1.00 was only 4.75% in our study.
